Filing Details
- Accession Number:
- 0001181431-13-050917
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-09-27 18:11:42
- Reporting Period:
- 2013-09-25
- Filing Date:
- 2013-09-27
- Accepted Time:
- 2013-09-27 18:11:42
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1396814 | Pacira Pharmaceuticals Inc. | PCRX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1545282 | Taunia Markvicka | C/O Pacira Pharmaceuticals, Inc. 5 Sylvan Way, Suite 100 Parsippany NJ 07054 | Vice President, Commercial | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-09-25 | 10,000 | $5.49 | 10,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-09-25 | 10,000 | $47.00 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (right to buy) | Disposition | 2013-09-25 | 10,000 | $0.00 | 10,000 | $5.49 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
8,349 | 2020-12-28 | No | 4 | M | Direct |
Footnotes
- The exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- The stock option vests as follows: 25% of the options vested on December 29, 2011; the remaining options vest in successive equal monthly installments over the subsequent 36 months.